Research for immunotherapy of glioblastoma with autologous heat shock protein gp96
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2017
At a glance
- Drugs HSP Gp96 vaccine (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cure&Sure Biotech
- 10 Dec 2015 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov.
- 10 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jul 2013 New trial record